The proof of DCVax efficacy was given at NYAS and every presentation given by Ashkan and and Liau.
We learned at ASCO that Sawston can serve 12K patients a year. That's 1-2 billion per year in revenue.
MHRA endorsed trial design by applying it to the pediatric study which they allowed to be ran post approval.
You can keep ignoring the facts and attacking management but the proof has been shown many times. DCVax works, it will be approved, and shareholders are going to be extremely well compensated for supporting Northwest Biotherapeutics management who work on our behalf as shareholders.